Plus Therapeutics (PSTV) Competitors $0.58 +0.10 (+21.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.57 -0.02 (-3.08%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PSTV vs. HYPR, SRTS, ZYXI, CTSO, MDAI, RBOT, SPAI, ICCM, SURG, and EDAPShould you be buying Plus Therapeutics stock or one of its competitors? The main competitors of Plus Therapeutics include Hyperfine (HYPR), Sensus Healthcare (SRTS), Zynex (ZYXI), Cytosorbents (CTSO), Spectral AI (MDAI), Vicarious Surgical (RBOT), Safe Pro Group (SPAI), IceCure Medical (ICCM), SurgePays (SURG), and EDAP TMS (EDAP). These companies are all part of the "medical equipment" industry. Plus Therapeutics vs. Its Competitors Hyperfine Sensus Healthcare Zynex Cytosorbents Spectral AI Vicarious Surgical Safe Pro Group IceCure Medical SurgePays EDAP TMS Plus Therapeutics (NASDAQ:PSTV) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do analysts prefer PSTV or HYPR? Plus Therapeutics presently has a consensus price target of $10.83, suggesting a potential upside of 1,751.85%. Hyperfine has a consensus price target of $1.06, suggesting a potential upside of 2.91%. Given Plus Therapeutics' higher probable upside, analysts plainly believe Plus Therapeutics is more favorable than Hyperfine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Plus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Hyperfine 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has more risk and volatility, PSTV or HYPR? Plus Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Which has higher valuation & earnings, PSTV or HYPR? Plus Therapeutics has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPlus Therapeutics$5.82M6.08-$12.98M-$2.94-0.20Hyperfine$12.89M6.22-$40.72M-$0.54-1.91 Do institutionals and insiders hold more shares of PSTV or HYPR? 3.3% of Plus Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 0.8% of Plus Therapeutics shares are held by insiders. Comparatively, 31.0% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer PSTV or HYPR? In the previous week, Hyperfine had 3 more articles in the media than Plus Therapeutics. MarketBeat recorded 5 mentions for Hyperfine and 2 mentions for Plus Therapeutics. Hyperfine's average media sentiment score of 0.35 beat Plus Therapeutics' score of -0.17 indicating that Hyperfine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Hyperfine 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is PSTV or HYPR more profitable? Hyperfine has a net margin of -343.42% compared to Plus Therapeutics' net margin of -520.90%. Plus Therapeutics' return on equity of 0.00% beat Hyperfine's return on equity.Company Net Margins Return on Equity Return on Assets Plus Therapeutics-520.90% N/A -202.73% Hyperfine -343.42%-74.19%-62.40% SummaryHyperfine beats Plus Therapeutics on 11 of the 15 factors compared between the two stocks. Get Plus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PSTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PSTV vs. The Competition Export to ExcelMetricPlus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.22M$2.46B$5.48B$9.51BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-0.208.9728.6723.80Price / Sales6.08437.63373.9066.58Price / CashN/A157.7635.4557.96Price / Book-0.384.838.275.55Net Income-$12.98M$31.62M$3.24B$259.03M7 Day Performance10.42%-5.28%-3.69%-4.59%1 Month Performance90.43%4.38%4.33%4.46%1 Year Performance-66.18%-2.49%25.95%18.03% Plus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PSTVPlus Therapeutics2.1993 of 5 stars$0.59+21.1%$10.83+1,751.9%-67.5%$29.22M$5.82M-0.2020Gap UpHYPRHyperfine1.0367 of 5 stars$0.97+5.3%$1.06+9.4%-11.2%$71.61M$12.89M-1.79190SRTSSensus Healthcare1.934 of 5 stars$4.60+6.0%$11.67+153.6%-10.7%$71.37M$41.81M46.0040News CoverageUpcoming EarningsGap DownZYXIZynex2.589 of 5 stars$2.34+1.3%$5.50+135.0%-84.9%$69.85M$192.35M-9.75770News CoverageAnalyst UpgradeGap DownCTSOCytosorbents1.1869 of 5 stars$1.04+1.0%$5.50+428.8%-24.4%$64.49M$35.60M-3.71220News CoverageUpcoming EarningsGap UpMDAISpectral AI2.2838 of 5 stars$2.44-2.8%$4.75+94.7%+43.9%$63.55M$29.58M-4.5283RBOTVicarious Surgical0.8831 of 5 stars$10.39+0.8%$8.50-18.2%+36.2%$61.15MN/A-0.99210News CoverageSPAISafe Pro Group0.7974 of 5 stars$3.74-6.5%$8.00+113.9%N/A$60.69M$2.17M-4.6211ICCMIceCure Medical2.0581 of 5 stars$1.02-0.5%$2.50+146.3%+52.3%$59.87M$3.29M-3.6260SURGSurgePays3.2477 of 5 stars$2.96+1.7%$9.00+204.1%-0.7%$59.40M$60.88M0.0040EDAPEDAP TMS2.8073 of 5 stars$1.51-0.7%$8.50+462.9%-73.1%$56.84M$69.18M-2.44230 Related Companies and Tools Related Companies Hyperfine Competitors Sensus Healthcare Competitors Zynex Competitors Cytosorbents Competitors Spectral AI Competitors Vicarious Surgical Competitors Safe Pro Group Competitors IceCure Medical Competitors SurgePays Competitors EDAP TMS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PSTV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Plus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Plus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
